Gilead Sciences Announces Late-Breaking Clinical Data And Real-World Evidence To Be Presented At HIV Glasgow As Co Extends Leadership Efforts Toward Ending The Epidemic
Gilead Sciences Announces Late-Breaking Clinical Data And Real-World Evidence To Be Presented At HIV Glasgow As Co Extends Leadership Efforts Toward Ending The Epidemic
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic.– Full Results From PURPOSE 2 Study Exploring Lenacapavir as a Potential Twice-Yearly HIV Prevention Option Among a Broad and Geographically Diverse Range of Cisgender Men and Gender-Diverse People –
–PURPOSE 2研究完整結果：探討Lenacapavir作爲Twice-Yearly HIV預防選擇在廣泛和地理多樣化的Cisgender男性和性別多樣化人群中的潛力–
– Four-Year Outcomes From Real-World BICSTaR Study Further Demonstrate the Consistent Efficacy and Safety Profile of Biktarvy, Providing Insights for HIV Clinical Care –
–來自實際BICSTaR研究的四年結果進一步展示Biktarvy的一致療效和安全性概況，爲HIV臨床護理提供見解–
– Late-Breaking Oral Presentation From Phase 2 Study Evaluating an Investigational Once-Weekly Oral Combination Treatment Regimen of Islatravir/Lenacapavir –
–來自第2期研究的Late-Breaking口頭報告，評估一種調查中的每週一次口服組合治療方案——Islatravir/Lenacapavir–
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13. The results from more than 40 studies across HIV treatment and prevention include late-breaking data and seven oral presentations. These findings reflect a robust portfolio and future-looking pipeline focused on person-centered drug development strategies to address unmet needs in HIV and help end the epidemic.
吉利德科學公司（納斯達克：GILD）今天宣佈將於2024年11月10日至13日在國際HIV感染藥物治療大會（HIV Glasgow 2024）上發佈HIV研究結果。這些結果涵蓋了40多項有關HIV治療和預防的研究，其中包括最新數據和七場口頭報告。這些發現體現了一個強大的產品組合和未來展望的管線，側重於以人爲中心的藥物開發策略，以解決HIV領域的需求並幫助終結這一流行病。